ARLENE M. MORRIS - Corporate Board Profile

PALATIN TECHNOLOGIES INC

Filing Date	Source Excerpt
2015-04-24	Arlene M. Morris is a nominee for director. Since March 2012 she has been Chief Executive Officer of Syndax Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on the development and commercialization of an epigenetic therapy for treatment-resistant cancers, President since September 2013 and a member of the board of directors since May 2011. ... Ms. Morris has extensive experience in the biotechnology industry, including prior leadership positions, current senior management and board service, and experience as chief executive officer of companies with product candidates in phase 3 clinical trials.
2016-04-22	Arlene M. Morris has been a director of Palatin since June 2015. ... (2) Member of the compensation committee. (3) Member of the nominating and corporate governance committee. ... Arlene Morris received $0 in fees earned or paid in cash, $21,600 in stock awards, and $13,984 in option awards, totaling $35,584.
2017-04-28	Arlene M. Morris has been a director of Palatin since June 2015. Since May 2015 she has served as the chief executive officer of Willow Advisors, LLC. From April 2012 until May 2015 she was President and Chief Executive Officer of Syndax Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on the development and commercialization of an epigenetic therapy for treatment-resistant cancers, and was a member of the board of directors from May 2011 until May 2015. From 2003 to January 2011, Ms. Morris served as the President, Chief Executive Officer and a member of the board of directors of Affymax, Inc., a publicly traded biotechnology company. Ms. Morris has also held various management and executive positions at Clearview Projects, Inc., a corporate advisory firm, Coulter Pharmaceutical, Inc., a publicly traded pharmaceutical company, Scios Inc., a publicly traded biopharmaceutical company, and Johnson & Johnson, a publicly traded healthcare company. She is currently a member of the board of directors of Viveve Medical, Inc., a publicly trade female healthcare medical device company, Dimension Therapeutics, Inc., a publicly traded gene therapy company, and Neovacs, SA, a French publicly traded biotechnology company, and was a director of Biodel Inc., a publicly traded specialty pharmaceutical company, from 2015 until its merger with Albireo Limited in 2016. Ms. Morris received a B.A. in Biology and Chemistry from Carlow College.
2018-05-17	ARLENE M. MORRIS has been a director of Palatin since June 2015... Compensation committee includes Ms. Morris... Nominating and corporate governance committee includes Ms. Morris... Compensation table shows total compensation of $82,726.
2019-05-10	Arlene M. Morris has been a director of Palatin since June 2015. Since May 2015 she has served as the chief executive officer of Willow Advisors, LLC. From April 2012 until May 2015, she was President and Chief Executive Officer of Syndax Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on the development and commercialization of an epigenetic therapy for treatment-resistant cancers, and was a member of the board of directors from May 2011 until May 2015. From 2003 to January 2011, Ms. Morris served as the President, Chief Executive Officer and a member of the board of directors of Affymax, Inc., a publicly traded biotechnology company. Ms. Morris has also held various management and executive positions at Clearview Projects, Inc., a corporate advisory firm, Coulter Pharmaceutical, Inc., a publicly traded pharmaceutical company, Scios Inc., a publicly traded biopharmaceutical company, and Johnson & Johnson, a publicly traded healthcare company. She is currently a member of the board of directors of Viveve Medical, Inc., a publicly traded female healthcare medical device company, miRagen Therapeutics, Inc., a publicly traded microRNA therapeutics company, and Neovacs, SA, a French publicly traded biotechnology company, and was a director of Biodel Inc., a publicly traded specialty pharmaceutical company, from 2015 until its merger with Albireo Limited in 2016, and Dimension Therapeutics, Inc., a publicly traded gene therapy company, until its acquisition by Ultragenyx Pharmaceutical Inc. in 2017. Ms. Morris received a B.A. in Biology and Chemistry from Carlow College. Ms. Morris serves on the Compensation Committee and the Nominating and Corporate Governance Committee. For fiscal 2018, Ms. Morris received total compensation of $140,275.
2020-05-11	Arlene M. Morris has been a director of Palatin since June 2015. She is a member of the compensation committee and the nominating and corporate governance committee. For fiscal 2019, she received total compensation of $138,300.
2021-04-26	Arlene M. Morris has been a director of Palatin since June 2015... She is a member of the compensation and nominating and corporate governance committees. Director compensation table shows total compensation of $138,450.
2022-05-24	Arlene M. Morris has been a director of Palatin since June 2015. (2) Member of the compensation committee. (3) Member of the nominating and corporate governance committee. The following table sets forth the compensation we paid to all directors during fiscal 2021, except for Dr. Spana, whose compensation is set forth below in the Fiscal 2021 Summary Compensation Table and related disclosure. Arlene Morris 53,750 fees earned or paid in cash, 42,500 stock awards, 42,500 option awards, total 138,750.
2023-05-19	Arlene M. Morris has been a director of Palatin since June 2015. Since May 2015 she has served as the chief executive officer of Willow Advisors, LLC, a consultancy to biotech companies on business development, commercial development and corporate strategy. From April 2012 until May 2015, she was President and Chief Executive Officer of Syndax Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on the development and commercialization of an epigenetic therapy for treatment-resistant cancers, and was a member of the board of directors from May 2011 until May 2015. From 2003 to January 2011, Ms. Morris served as the President, Chief Executive Officer and a member of the board of directors of Affymax, Inc., a publicly traded biotechnology company. Ms. Morris has also held various management and executive positions at Clearview Projects, Inc., a corporate advisory firm, Coulter Pharmaceutical, Inc., a publicly traded pharmaceutical company, Scios Inc., a publicly traded biopharmaceutical company, and Johnson & Johnson, a publicly traded healthcare company. She is currently a member of the board of directors Viridian Therapeutics, Inc., a publicly traded therapeutic antibody company, and Cogent Biosciences, Inc., a publicly traded oncology biopharmaceutical company, and was previously a director of Viveve Medical, Inc., a publicly traded female healthcare medical device company, until February 2023, Neovacs SA, a publicly traded French company, Biodel Inc., a publicly traded specialty pharmaceutical company, from 2015 until its merger with Albireo Limited in 2016, and Dimension Therapeutics, Inc., a publicly traded gene therapy company, until its acquisition by Ultragenyx Pharmaceutical Inc. in 2017. Ms. Morris received a B.A. in Biology and Chemistry from Carlow College. Ms. Morris has extensive experience in the biotechnology industry, including prior leadership positions, senior management, and board service, and experience as chief executive officer of companies with product candidates in phase 3 clinical trials.
2024-05-28	Arlene M. Morris has been a director of Palatin since June 2015. She is a member of the compensation committee and nominating and corporate governance committee. Compensation table shows total compensation of $97,466.